Press Release
Puerto Rico Pharmacies Agree to Pay $4.6 Million to Federal Authorities in Medicare and Medicaid Fraud Cases
For Immediate Release
U.S. Attorney's Office, District of Puerto Rico
San Juan, Puerto Rico – The United States Attorney’s Office for the District of Puerto Rico has recovered over $4.1 million from four Puerto Rico pharmacies and their owners during the period from February 26 to May 28, 2026.
The pharmacies and owners have agreed to pay $4.6 million to resolve allegation of Medicare and Medicaid fraud between January 2021 and January 2024, for billing for diverted prescriptions sold to unsuspecting patients which had been misrepresented as properly sourced, despite unverifiable origins. Officials warn that such practices threaten patient safety and the integrity of federal health programs, which require medications to come from approved distributors. Diverted drugs may be improperly stored or handled, affecting their safety and effectiveness. The below-listed pharmacies and their owners agreed to pay and have paid the civil penalties outlined below:
Pharmacy | Owner(s) | Amount of Penalties | Amount of Penalties Collected to Date
|
Farmacia Unity (Aibonito)
| Raúl Morera Enid Rivera | $600,000 | $165,000 |
Farmacia La Rampla (Yabucoa)
| Edwin Gómez | $1,000,000 | $1,000,000 |
Farmacia Monte Verde (Bayamón)
| María T. Rivera Valerie Cintrón | $1,000,000 | $1,000,000 |
Farmacia Santa Olaya (Bayamón) | Jaime Figueroa | $2,000,000 |
$2,000,000
|
These cases were investigated by the U.S. Attorney’s Office for the District of Puerto Rico, the Department of Health and Human Services Office of Inspector General, and the Food and Drug Administration’s Office of Criminal Investigations, with support from other federal and local agencies.
U.S. Attorney W. Stephen Muldrow of the District of Puerto Rico made the announcement. Assistant U.S. Attorney Rafael López Rivera investigated and prosecuted the cases.
The claims resolved by the settlement are allegations only and there has been no determination of liability.
###
Updated June 4, 2026
Topics
Prescription Drugs
Healthcare Fraud
Component